(Q44645535)

5 December 2017

title

Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly (English)

1 reference

5 December 2017

Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly (English)

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

29 March 2024

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

29 March 2024

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

29 March 2024

9

Annamaria Colao

1 reference

5 December 2017

3

Rosario Pivonello

1 reference

5 December 2017

1

Roberto Attanasio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14602759

29 March 2024

author name string

Roberto Baldelli

2

1 reference

5 December 2017

Silvia Grottoli

4

1 reference

5 December 2017

Liliana Bocca

5

1 reference

5 December 2017

Valentina Gasco

6

1 reference

5 December 2017

Massimo Giusti

7

1 reference

5 December 2017

Guido Tamburrano

8

1 reference

5 December 2017

Renato Cozzi

10

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

5 December 2017

published in

The Journal of Clinical Endocrinology and Metabolism

1 reference

5 December 2017

volume

88

1 reference

5 December 2017

issue

11

1 reference

5 December 2017

page(s)

5258-5265

1 reference

Growth-hormone and prolactin excess.

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

29 March 2024

Mortality in acromegaly

2

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

An audit of outcome of treatment in acromegaly.

29 March 2024

3

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Determinants of clinical outcome and survival in acromegaly

29 March 2024

4

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Guidelines for acromegaly management

29 March 2024

6

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Somatostatin analogs in acromegaly

29 March 2024

9

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

29 March 2024

11

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

29 March 2024

13

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Clinical results of long-term slow-release lanreotide treatment of acromegaly

29 March 2024

17

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

29 March 2024

18

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide

29 March 2024

19

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.

29 March 2024

20

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

29 March 2024

21

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).

29 March 2024

23

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.

29 March 2024

24

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.

29 March 2024

25

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Slow-release lanreotide treatment in acromegaly: effects on quality of life.

29 March 2024

26

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog)

29 March 2024

27

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly

29 March 2024

29

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.

29 March 2024

30

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

29 March 2024

32

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly

29 March 2024

33

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration

29 March 2024

34

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Pharmacotherapy or surgery as primary treatment for acromegaly?

29 March 2024

36

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma

29 March 2024

37

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Pituitary surgery for the management of acromegaly

29 March 2024

38

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Failure of radiotherapy in acromegaly

29 March 2024

40

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study

29 March 2024

41

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

29 March 2024

43

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

29 March 2024

44

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

29 March 2024

46

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

29 March 2024

47

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

29 March 2024

48

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group

29 March 2024

49

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

29 March 2024

51

1 reference

https://api.crossref.org/works/10.1210/JC.2003-030266

29 March 2024

Identifiers

1 reference

5 December 2017

1 reference